AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

PEN · NYSE · Medical - Devices

Penumbra (PEN)

Builds clot-removal, embolization, and vascular-access devices for neurovascular and peripheral procedures.

$318.91

vs last close+0.13 (+0.04%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	271	285	279	299	301	316	324	339	355	385	375	390
Cost of revenue	93	98	98	137	101	105	108	115	114	123	121	125
Gross profit	178	187	181	163	200	211	216	224	240	262	253	265
	165	152	169	244	165	168	176	183	192	203	215	224
Research & development	21	22	25	25	25	20	22	23	23	22	22	25
Selling, general & administrative	126	130	144	142	140	148	153	160	169	181	193	199
Other expenses	18	0	0	77	0	0	0	0	0	0	0	0
Operating income	13	35	12	−81	35	43	40	41	49	59	38	41
	1	3	3	3	4	2	4	4	3	4	3	5
Interest income	1	3	3	4	3	3	3	4	4	5	5	6
Interest expense	0	0	0	0	0	0	0	0	0	0	0	0
Other non-operating income	−18	10	−3	−3	−5	−2	−4	−5	−4	−5	−4	−5
Income before tax	13	38	15	−78	40	44	44	45	52	64	42	46
Income tax expense	4	−16	4	−18	10	11	5	0	6	16	9	11
Net income from continuing operations	9	54	11	−60	30	34	39	45	46	47	33	35
Net income	9	54	11	−60	30	34	39	45	46	47	33	35
EPS, basic	$0.24	$1.40	$0.28	−$1.55	$0.76	$0.88	$1.02	$1.17	$1.17	$1.21	$0.83	$0.88
EPS, diluted	$0.23	$1.38	$0.28	−$1.55	$0.75	$0.86	$1.00	$1.15	$1.17	$1.20	$0.82	$0.88
Weighted average shares, basic	38	39	39	39	39	39	39	39	39	39	39	39
Weighted average shares, diluted	39	39	39	39	39	39	39	39	39	39	40	40
EBITDA	38	32	23	−70	44	49	49	51	55	68	47	52
Depreciation & amortization	7	7	8	8	4	4	5	6	2	4	5	6
EBIT	31	25	15	−78	40	45	44	46	53	64	42	46